Press Release - 2025-11-04
Press Release - 2025-09-18
Seaport Therapeutics to Participate in Upcoming Investor Conferences
Press Release - 2025-09-11
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers
Press Release - 2025-07-17
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Press Release - 2025-04-24
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
Press Release - 2025-03-31
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
Press Release - 2025-03-11
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Press Release - 2025-03-03
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Press Release - 2025-02-21
